Irinotecan Amarox

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecan Amarox, is a topoisomerase I inhibitor presented as an injectable solution for intravenous use. It is employed in the treatment of metastatic colorectal cancer in adult patients. It belongs to the antineoplastic therapeutic class and is marketed in the European Union.

GNH USA supplies Irinotecan Amarox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The product complies with European Union regulatory standards and is distributed under strict quality‑assured conditions.

Irinotecan Amarox is indicated for colorectal cancer indications where topoisomerase I inhibition is part of the therapeutic strategy.

- Metastatic colorectal cancer: improves overall survival and disease control in adult patients with metastatic disease. - Advanced colorectal cancer: used in combination regimens to reduce tumor burden and delay progression. - Recurrent colorectal cancer: administered after prior therapy to achieve tumor response and prolong progression‑free interval.

Irinotecan therapy is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting - Diarrhea - Neutropenia - Fatigue - Alopecia

Serious or Rare Side Effects: - Febrile neutropenia - Severe or febrile diarrhea (colitis) - Hepatic toxicity (elevated transaminases) - Allergic reactions (rash, anaphylaxis) - Pulmonary toxicity (interstitial pneumonitis)

Prior to initiating Irinotecan Amarox, clinicians should assess several clinical parameters and follow specific safety measures. - Baseline blood counts: obtain complete blood count with differential to monitor for neutropenia. - Liver function: evaluate hepatic enzymes because impairment can increase SN‑38 exposure. - Renal function: assess creatinine clearance as renal excretion contributes to drug clearance. - Hypersensitivity: avoid use in patients with known allergy to irinotecan or formulation excipients. - Dose adjustments: consider reduced dosing in patients with moderate hepatic impairment. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan may interact with other medicines that affect its metabolism or increase overlapping toxicities.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce SN‑38 levels and efficacy. - Potent UGT1A1 inhibitors (e.g., atazanavir, indinavir): can raise SN‑38 exposure and heighten toxicity. - Concurrent myelosuppressive agents (e.g., high‑dose cyclophosphamide): increase risk of severe neutropenia.

Moderate Interactions (Monitor Closely): - Anticholinergic drugs (e.g., atropine): may mask early signs of diarrhea. - Antiemetics such as ondansetron: may be required to control nausea but can affect QT interval. - Anticoagulants (e.g., warfarin): monitor coagulation parameters as irinotecan can enhance bleeding risk.